Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
JYNT Stock Forecast 2025-2026
$8.47
Current Price
$128.65M
Market Cap
Buy 2
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to JYNT Price Targets
+65.3%
To High Target of $14.00
+18.1%
To Median Target of $10.00
+6.3%
To Low Target of $9.00
JYNT Price Momentum
+0.6%
1 Week Change
+10.4%
1 Month Change
-26.9%
1 Year Change
-20.3%
Year-to-Date Change
-37.1%
From 52W High of $13.47
+12.9%
From 52W Low of $7.50
📊 TOP ANALYST CALLS
Did JYNT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Joint Corp is one of their latest high-conviction picks.
Latest JYNT Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, JYNT has a neutral consensus with a median price target of $10.00 (ranging from $9.00 to $14.00). The overall analyst rating is N/A (N/A/10). Currently trading at $8.47, the median forecast implies a 18.1% upside. This outlook is supported by 2 Buy, 3 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
JYNT Analyst Ratings
2
Buy
3
Hold
0
Sell
JYNT Price Target Range
Low
$9.00
Average
$10.00
High
$14.00
Current: $8.47
Latest JYNT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for JYNT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 8, 2025 | B. Riley Securities | Jeff Van Sinderen | Buy | Maintains | $18.00 |
| May 9, 2025 | Lake Street | Ryan Meyers | Buy | Maintains | $16.00 |
| Nov 8, 2024 | Roth MKM | George Kelly | Buy | Maintains | $15.00 |
| May 6, 2024 | B. Riley Securities | Jeff Van Sinderen | Buy | Maintains | $20.00 |
| May 3, 2024 | Roth MKM | George Kelly | Buy | Reiterates | $16.00 |
| Sep 14, 2023 | Roth MKM | George Kelly | Buy | Maintains | $13.00 |
| Aug 11, 2023 | Roth MKM | Buy | Maintains | $N/A | |
| Aug 11, 2023 | Maxim Group | Hold | Downgrade | $N/A | |
| Mar 13, 2023 | DA Davidson | Linda Bolton Weiser | Neutral | Upgrade | $15.00 |
| Aug 8, 2022 | DA Davidson | Linda Bolton Weiser | Underperform | Maintains | $12.00 |
| Aug 5, 2022 | B. Riley Securities | Jeff Van Sinderen | Buy | Upgrade | $31.00 |
| Aug 5, 2022 | Maxim Group | Anthony Vendetti | Buy | Upgrade | $36.00 |
| May 10, 2022 | DA Davidson | Linda Bolton Weiser | Underperform | Downgrade | $13.00 |
| May 9, 2022 | DA Davidson | Linda Bolton Weiser | Underperform | Downgrade | $13.00 |
| May 6, 2022 | Craig-Hallum | Hold | Downgrade | $N/A | |
| Feb 25, 2022 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $69.00 |
| Aug 9, 2021 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $128.00 |
| Aug 6, 2021 | Roth Capital | George Kelly | Buy | Maintains | $105.00 |
| Jun 28, 2021 | Roth Capital | George Kelly | Buy | Maintains | $100.00 |
| Jun 3, 2021 | Maxim Group | Hold | Downgrade | $N/A |
The Joint Corp. (JYNT) Competitors
The following stocks are similar to Joint Corp based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
The Joint Corp. (JYNT) Financial Data
The Joint Corp. has a market capitalization of $128.65M with a P/E ratio of 66.0x. The company generates $54.18M in trailing twelve-month revenue with a -1.5% profit margin.
Revenue growth is +5.7% quarter-over-quarter, while maintaining an operating margin of +2.0% and return on equity of -1.0%.
Valuation Metrics
Market Cap
$128.65M
Enterprise Value
$98.33M
P/E Ratio
66.0x
PEG Ratio
-0.5x
Price/Sales
2.4x
Growth & Margins
Revenue Growth (YoY)
+5.7%
Gross Margin
+80.1%
Operating Margin
+2.0%
Net Margin
-1.5%
EPS Growth
-55.7%
Financial Health
Cash/Price Ratio
+23.6%
Current Ratio
1.8x
Debt/Equity
9.2x
ROE
-1.0%
ROA
+0.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
The Joint Corp. (JYNT) Business Model
About The Joint Corp.
What They Do
Provides accessible chiropractic care through clinics.
Business Model
The company operates a franchise model, allowing for rapid expansion and accessibility of its chiropractic services without the need for insurance or appointments. It utilizes a subscription-based model, which creates consistent revenue streams and encourages ongoing care for its clients.
Additional Information
The Joint Corp. caters to the growing demand for non-invasive health solutions and emphasizes convenience and customer-centricity in its services. Its innovative approach positions it as an emerging leader in the chiropractic care sector and reflects the increasing consumer preference for holistic and preventive health solutions.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
443
CEO
Mr. Sanjiv Razdan
Country
United States
IPO Year
2014
Website
www.thejoint.comThe Joint Corp. (JYNT) Latest News & Analysis
Latest News
Quick Summary
A news excerpt from Scottsdale highlights that the holiday season can strain back health. Investors in health and wellness sectors may find opportunities in related products or services.
Why It Matters
The mention of holiday stress on health may indicate increased demand for wellness products and services, impacting related stocks and consumer spending trends.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The Joint Corp. (JYNT) will hold its Q3 2025 earnings call on November 6, 2025, at 5:00 PM EST, featuring CEO Sanjiv Razdan and CFO Scott Bowman.
Why It Matters
The earnings call indicates upcoming financial results for The Joint Corp., which can influence stock performance and investor sentiment based on earnings, forecasts, and management insights.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
The Joint Corp. (JYNT) reported Q3 earnings of $0.02 per share, surpassing the Zacks Consensus Estimate of a loss of $0.01. This is a decrease from $0.04 per share a year earlier.
Why It Matters
The Joint Corp. reported better-than-expected earnings, indicating potential growth and improving financial health, which could boost investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The Joint Corp. (NASDAQ: JYNT) has been recognized in the Franchise Times Top 400, highlighting its position as the largest provider of chiropractic care in the U.S.
Why It Matters
The Joint Corp.'s recognition on the Franchise Times Top 400 enhances its brand reputation, potentially attracting more franchisees and increasing revenue, positively impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
The Joint Chiropractic Debuts in Delaware
2 months ago
Quick Summary
The Joint Corp. (NASDAQ: JYNT) has opened its first chiropractic clinic in Delaware, marking its expansion into the state.
Why It Matters
The opening of a new clinic in Delaware expands The Joint Corp.'s market presence, potentially increasing revenue and attracting more investors due to growth opportunities.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A new Chief Marketing Officer (CMO) with significant expertise in brand building, franchising, and strategic growth has been appointed, potentially enhancing the company's market position.
Why It Matters
A CMO with strong expertise can enhance a company's brand value, drive sales, and improve market positioning, potentially leading to increased investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About JYNT Stock
What is The Joint Corp.'s (JYNT) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, The Joint Corp. (JYNT) has a median price target of $10.00. The highest price target is $14.00 and the lowest is $9.00.
Is JYNT stock a good investment in 2026?
According to current analyst ratings, JYNT has 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for JYNT stock?
Wall Street analysts predict JYNT stock could reach $10.00 in the next 12 months. This represents a 18.1% increase from the current price of $8.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is The Joint Corp.'s business model?
The company operates a franchise model, allowing for rapid expansion and accessibility of its chiropractic services without the need for insurance or appointments. It utilizes a subscription-based model, which creates consistent revenue streams and encourages ongoing care for its clients.
What is the highest forecasted price for JYNT The Joint Corp.?
The highest price target for JYNT is $14.00 from at , which represents a 65.3% increase from the current price of $8.47.
What is the lowest forecasted price for JYNT The Joint Corp.?
The lowest price target for JYNT is $9.00 from at , which represents a 6.3% increase from the current price of $8.47.
What is the overall JYNT consensus from analysts for The Joint Corp.?
The overall analyst consensus for JYNT is neutral. Out of 6 Wall Street analysts, 2 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are JYNT stock price projections?
Stock price projections, including those for The Joint Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 5:22 PM UTC